Greenwich LifeSciences (GLSI) said the European Medicines Agency (EMA) approved the use of its commercially manufactured GP2 immunotherapy in its ongoing Phase III FLAMINGO-01 breast cancer trial. The regulatory nod supports trial execution using the intended commercial supply and reduces execution/manufacturing risk. Overall, the update is a positive clinical/regulatory milestone, though with no quantified financial impact disclosed.
Greenwich LifeSciences (GLSI) said the European Medicines Agency (EMA) approved the use of its commercially manufactured GP2 immunotherapy in its ongoing Phase III FLAMINGO-01 breast cancer trial. The regulatory nod supports trial execution using the intended commercial supply and reduces execution/manufacturing risk. Overall, the update is a positive clinical/regulatory milestone, though with no quantified financial impact disclosed.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
